## Annick Barbaud

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1863508/publications.pdf Version: 2024-02-01



#	Article	lF	CITATIONS
1	Skin test concentrations for systemically administered drugs – an <scp>ENDA</scp> / <scp>EAACI</scp> Drug Allergy Interest Group position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 702-712.	2.7	656
2	Guidelines for performing skin tests withdrugs in the investigation of cutaneous adverse drug reactions. Contact Dermatitis, 2001, 45, 321-328.	0.8	439
3	A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions. British Journal of Dermatology, 2013, 168, 555-562.	1.4	304
4	Skin testing in patients with hypersensitivity reactions to iodinated contrast media – a European multicenter study. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 234-241.	2.7	295
5	Towards a more precise diagnosis of hypersensitivity to betaâ€lactams — an EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1300-1315.	2.7	182
6	EAACI position paper on how to classify cutaneous manifestations of drug hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 14-27.	2.7	149
7	Controversies in drug allergy: Testing for delayed reactions. Journal of Allergy and Clinical Immunology, 2019, 143, 66-73.	1.5	144
8	Cumulative Incidence of, Risk Factors for, and Outcome of Dermatological Complications of Anti-TNF Therapy in Inflammatory Bowel Disease: A 14-Year Experience. American Journal of Gastroenterology, 2015, 110, 1186-1196.	0.2	105
9	Contact allergy in chronic leg ulcers: results of a multicentre study carried out in 423 patients and proposal for an updated series of patch tests. Contact Dermatitis, 2009, 60, 279-287.	0.8	99
10	Skin Testing and Patch Testing in Non-IgE-Mediated Drug Allergy. Current Allergy and Asthma Reports, 2014, 14, 442.	2.4	99
11	Approach to the diagnosis of drug hypersensitivity reactions: similarities and differences between Europe and North America. Clinical and Translational Allergy, 2017, 7, 7.	1.4	79
12	Relevance of skin tests with drugs in investigating cutaneous adverse drug reactions. Contact Dermatitis, 2001, 45, 265-268.	0.8	69
13	Analysis of cross-reactivity among radiocontrast media in 97 hypersensitivity reactions. Journal of Allergy and Clinical Immunology, 2016, 137, 633-635.e4.	1.5	59
14	Practice parameters for diagnosing and managing iodinated contrast media hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1325-1339.	2.7	58
15	Allergies and COVIDâ€19 vaccines: An ENDA/EAACI Position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2292-2312.	2.7	55
16	Contact sensitization to modern dressings: a multicentre study on 354 patients with chronic leg ulcers. Contact Dermatitis, 2015, 72, 90-96.	0.8	51
17	Airborne allergic contact dermatitis caused by isothiazolinones in waterâ€based paints: a retrospective study of 44 cases. Contact Dermatitis, 2017, 77, 163-170.	0.8	51
18	Hypersensitivity to proton pump inhibitors: Diagnostic accuracy of skin tests compared to oral provocation test. Journal of Allergy and Clinical Immunology, 2012, 130, 547-549.	1.5	50

ANNICK BARBAUD

#	Article	IF	CITATIONS
19	Outbreak of contact sensitization to methylisothiazolinone: an analysis of <scp>F</scp> rench data from the <scp>REVIDALâ€GERDA</scp> network. Contact Dermatitis, 2014, 70, 262-269.	0.8	48
20	A EAACI drug allergy interest group survey on how European allergy specialists deal with βâ€lactam allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1052-1062.	2.7	44
21	Drugâ€induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. British Journal of Clinical Pharmacology, 2019, 85, 570-579.	1.1	41
22	Nonâ€irritant concentrations and amounts of active ingredient in drug patch tests. Contact Dermatitis, 2014, 71, 170-175.	0.8	37
23	Intradermal Tests With Drugs: An Approach to Standardization. Frontiers in Medicine, 2020, 7, 156.	1.2	34
24	Mineral oils and waxes in cosmetics: an overview mainly based on the current European regulations and the safety profile of these compounds. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 5-14.	1.3	33
25	Sensitization to petrolatum: an unusual cause of false-positive drug patch-tests. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 1006-1009.	2.7	32
26	Skin tests in the workâ€up of cutaneous adverse drug reactions: A review and update. Contact Dermatitis, 2022, 86, 344-356.	0.8	31
27	Cutaneous Adverse Drug Reactions with Antimalarials and Allergological Skin Tests. Dermatology, 2015, 231, 353-359.	0.9	27
28	Place of Excipients in Systemic Drug Allergy. Immunology and Allergy Clinics of North America, 2014, 34, 671-679.	0.7	23
29	Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19: An EAACI Position Paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 2775-2793.	2.7	23
30	Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1â€antihistamine treatment: results of the phase <scp>IV</scp> openâ€label <scp>SUNRISE</scp> study. British Journal of Dermatology, 2019, 180, 56-66.	1.4	22
31	Mechanism and diagnosis of protein contact dermatitis. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 117-121.	1.1	20
32	Managing generalized interferon-induced eruptions and the effectiveness of desensitization. Clinical and Experimental Allergy, 2014, 44, 756-764.	1.4	19
33	lgE antibodies and skin tests in immediate hypersensitivity reactions to infliximab in inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2015, 27, 1200-1208.	0.8	19
34	Bullous drug eruption to <i>Nigella sativa</i> oil: Consideration of the use of a herbal medicine – clinical report and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2017, 31, e217-e219.	1.3	19
35	Systemic Allergy to Corticosteroids: Clinical Features and Cross Reactivity. Current Pharmaceutical Design, 2017, 22, 6825-6831.	0.9	19
36	ls a specific eyelid patch test series useful? Results of a French prospective study. Contact Dermatitis, 2018, 79, 157-161.	0.8	18

ANNICK BARBAUD

#	Article	IF	CITATIONS
37	Are drug intradermal tests dangerous to explore crossâ€reactivity and coâ€sensitization in DRESS?. British Journal of Dermatology, 2019, 181, 611-612.	1.4	16
38	Genetic variants associated with T cell–mediated cutaneous adverse drug reactions: A PRISMAâ€compliant systematic review—An EAACI position paper. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1069-1098.	2.7	16
39	DRESS and AGEP Reactions to Iodinated Contrast Media: A French Case Series. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3041-3050.	2.0	15
40	Skin Testing Approaches for Immediate and Delayed Hypersensitivity Reactions. Immunology and Allergy Clinics of North America, 2022, 42, 307-322.	0.7	11
41	Linear Immunoglobulin a Bullous Dermatosis in Children. Frontiers in Pediatrics, 0, 10, .	0.9	11
42	Management of hypersensitivity reactions to Tocilizumab. Clinical and Experimental Allergy, 2018, 48, 749-752.	1.4	10
43	Can we allow a further intake of drugs poorly suspected as responsible in drug reaction with eosinophilia and systemic symptoms ( <scp>DRESS</scp> )? A study of practice. Clinical and Experimental Allergy, 2019, 49, 924-928.	1.4	10
44	False positive results can occur on delayed reading of intradermal tests with cisplatin. Journal of Allergy and Clinical Immunology, 2010, 125, 1410-1411.	1.5	9
45	Risks associated with cosmetic ingredients. Annales De Dermatologie Et De Venereologie, 2021, 148, 77-93.	0.5	8
46	Multiple cases of sensitization to an antiseptic containing chlorhexidine digluconate/benzalkonium chloride/benzyl alcohol with different profiles of sensitization in adults and children. Contact Dermatitis, 2022, 87, 62-70.	0.8	8
47	What is the optimal duration for a <scp>ROAT</scp> ? The experience of the French Dermatology and Allergology group ( <scp>DAG</scp> ). Contact Dermatitis, 2022, 87, 170-175.	0.8	8
48	The European Standard Series and its additions: are they of any use in 2013?. European Journal of Dermatology, 2014, 24, 15-22.	0.3	7
49	Prurigo pigmentosa induced by ketosis ("keto rashâ€): a demonstrative case and internet search results. International Journal of Dermatology, 2020, 59, 876-877.	0.5	6
50	Sweet-like syndrome and multiple COVID arm syndrome following COVID-19 vaccines: â€~specific' patterns in a series of 192 patients. British Journal of Dermatology, 2022, 187, 615-617.	1.4	6
51	Eyelid allergic contact dermatitis after intravitreal injections of antiâ€vascular endothelial growth factor: What is the culprit? A report of 3 cases. Contact Dermatitis, 2018, 79, 103-104.	0.8	5
52	Thymoquinone as a causative allergen in <scp><i>Nigella sativa</i></scp> oil contact dermatitis with crossâ€reactivity to <i>t</i> ertâ€butylhydroquinone. Contact Dermatitis, 2020, 83, 132-134.	0.8	5
53	<i>Tert</i> â€butylhydroquinone is a marker for sensitivity to <scp><i>Nigella sativa</i></scp> oil allergy: Five new cases. Contact Dermatitis, 2021, 84, 447-449.	0.8	4
54	Occupational contact dermatitis caused by nickel in scratchcards. Contact Dermatitis, 2015, 73, 371-372.	0.8	3

ANNICK BARBAUD

#	Article	IF	CITATIONS
55	Systemic sclerosis is associated with lower limb vascular stiffness and microvascular impairment: results from a prospective study. Clinical Rheumatology, 2021, 40, 3679-3686.	1.0	3
56	Clinical and histological characteristics during chronic urticaria with dermal neutrophilic infiltrate: Proposal of a diagnostic score. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	3
57	Conduite à tenir devant une toxidermie aux corticoÃ <sup>-</sup> des. Revue Francaise D'allergologie, 2013, 53, 298-303.	0.1	2
58	Echocardiographic features in antiphospholipid-negative Sneddon's syndrome and potential association with severity of neurological symptoms or recurrence of strokes: a longitudinal cohort study. European Heart Journal Cardiovascular Imaging, 2021, 22, 119-128.	0.5	2
59	Occurrence of immediate and delayed hypersensitivity to hexamidine. Contact Dermatitis, 2021, 85, 580-582.	0.8	2
60	Performance accuracy, advantages and limitations of a store-and-forward teledermatology platform developed for general practitioners: A retrospective study of 298 cases. Annales De Dermatologie Et De Venereologie, 2022, 149, 245-250.	0.5	2
61	Can we allow a further intake of drugs poorly suspected as responsible in drug reaction with eosinophilia and systemic symptoms? A study of practice. Clinical and Experimental Allergy, 2019, 49, 1264-1264.	1.4	1
62	Two cases of allergic contact dermatitis to Tamanu oil. Contact Dermatitis, 2022, 87, 99-100.	0.8	0